Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Cancer Res

Retrieve available abstracts of 29 articles:
HTML format

Single Articles

    February 2023
  1. ZHANG H, Jin X, Huang H
    Deregulation of SPOP in Cancer.
    Cancer Res. 2023;83:489-499.
    PubMed     Abstract available

  2. FERRI-BORGOGNO S, Zhu Y, Sheng J, Burks JK, et al
    Spatial transcriptomics depict ligand-receptor crosstalk heterogeneity at the tumor-stroma interface in long-term ovarian cancer survivors.
    Cancer Res. 2023 Feb 14:CAN-22-1821. doi: 10.1158/0008-5472.CAN-22-1821.
    PubMed     Abstract available

    January 2023
  3. LLANO E, Todeschini AL, Felipe-Medina N, Corte-Torres MD, et al
    The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors.
    Cancer Res. 2023;83:239-250.
    PubMed     Abstract available

    December 2022
  4. JUNGLES KM, Green MD
    Fat Fuels the Fire in Cervical Cancer.
    Cancer Res. 2022;82:4513-4514.
    PubMed     Abstract available

  5. HAWKINS SM, Nephew KP
    Unintended Consequences of Antibiotic Therapy on the Microbiome Delivers a Gut Punch in Ovarian Cancer.
    Cancer Res. 2022;82:4511-4512.
    PubMed     Abstract available

  6. ALSINA-SANCHIS E, Mulfarth R, Moll I, Bohn S, et al
    Endothelial RBPJ Is Essential for the Education of Tumor-Associated Macrophages.
    Cancer Res. 2022;82:4414-4428.
    PubMed     Abstract available

    November 2022
  7. WANG CK, Chen TJ, Tan GYT, Chang FP, et al
    MEX3A mediates p53 degradation to suppress ferroptosis and facilitate ovarian cancer tumorigenesis.
    Cancer Res. 2022 Nov 10. pii: 710535. doi: 10.1158/0008-5472.CAN-22-1159.
    PubMed     Abstract available

    October 2022
  8. ATIYA HI, Frisbie L, Goldfeld E, Orellana T, et al
    Endometriosis-associated mesenchymal stem cells support ovarian clear cell carcinoma through iron regulation.
    Cancer Res. 2022 Oct 11. pii: 709712. doi: 10.1158/0008-5472.CAN-22-1294.
    PubMed     Abstract available

  9. MUHAMMAD N, Ruiz F, Stanley J, Rashmi R, et al
    Mono- and diunsaturated fatty acids sensitize cervical cancer to radiation therapy.
    Cancer Res. 2022 Oct 10. pii: 709678. doi: 10.1158/0008-5472.CAN-21-4369.
    PubMed     Abstract available

  10. CHAMBERS LM, Esakov Rhoades EL, Bharti R, Braley C, et al
    Disruption of the gut microbiota confers cisplatin resistance in epithelial ovarian cancer.
    Cancer Res. 2022 Oct 7. pii: 709668. doi: 10.1158/0008-5472.CAN-22-0455.
    PubMed     Abstract available

  11. WANG Y, Huang P, Wang BG, Murdock T, et al
    Spatial transcriptomic analysis of ovarian cancer precursors reveals reactivation of IGFBP2 during pathogenesis.
    Cancer Res. 2022 Oct 7. pii: 709669. doi: 10.1158/0008-5472.CAN-22-1620.
    PubMed     Abstract available

  12. HO GY, Kyran EL, Bedo J, Wakefield MJ, et al
    Epithelial-to-mesenchymal transition supports ovarian carcinosarcoma tumorigenesis and confers sensitivity to microtubule-targeting with eribulin.
    Cancer Res. 2022 Oct 7. pii: 709667. doi: 10.1158/0008-5472.CAN-21-4012.
    PubMed     Abstract available

  13. LU X, Xin DE, Du JK, Zou QC, et al
    Loss of LOXL2 promotes uterine hypertrophy and tumor progression by enhancing H3K36ac-dependent gene expression.
    Cancer Res. 2022 Oct 5. pii: 709611. doi: 10.1158/0008-5472.CAN-22-0848.
    PubMed     Abstract available

    September 2022
  14. ZHANG Y, Li J, Zhou Y, Li Z, et al
    And-1 Coordinates with the FANCM Complex to Regulate Fanconi Anemia Signaling and Cisplatin Resistance.
    Cancer Res. 2022;82:3249-3262.
    PubMed     Abstract available

    August 2022
  15. WANG Y, Xie H, Chang X, Hu W, et al
    Single-cell dissection of the multiomic landscape of high-grade serous ovarian cancer.
    Cancer Res. 2022 Aug 15. pii: 707741. doi: 10.1158/0008-5472.CAN-21-3819.
    PubMed     Abstract available

    July 2022
  16. CHENG L, Zhou S, Zhou S, Shi K, et al
    Dual inhibition of CDK12/CDK13 targets both tumor and immune cells in ovarian cancer.
    Cancer Res. 2022 Jul 20. pii: 707082. doi: 10.1158/0008-5472.CAN-22-0222.
    PubMed     Abstract available

    April 2022
  17. PELLEGRINO B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, et al
    Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
    Cancer Res. 2022;82:1646-1657.
    PubMed     Abstract available

    March 2022
  18. OSORIO JC, Zamarin D
    Beyond T Cells: IgA Incites Immune Recognition in Endometrial Cancer.
    Cancer Res. 2022;82:766-768.
    PubMed     Abstract available

  19. ZHANG S, Yan C, Millar DG, Yang Q, et al
    Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.
    Cancer Res. 2022;82:773-784.
    PubMed     Abstract available

    February 2022
  20. GHILARDI C, Moreira Barbosa C, Brunelli L, Ostano P, et al
    Cancer Res. 2022 Feb 7. pii: 0008-5472.CAN-21-1223.
    PubMed     Abstract available

    December 2021
  21. MANDAL G, Biswas S, Anadon CM, Yu X, et al
    IgA-dominated humoral immune responses govern patients' outcome in endometrial cancer.
    Cancer Res. 2021 Dec 23. pii: 0008-5472.CAN-21-2376.
    PubMed     Abstract available

  22. O'CONNOR CM, Taylor SE, Miller KM, Hurst L, et al
    Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma.
    Cancer Res. 2021 Dec 17. pii: 0008-5472.CAN-21-1987.
    PubMed     Abstract available

    November 2021
  23. KANAKKANTHARA A, Hou X, Ekstrom TL, Zanfagnin V, et al
    Repurposing ceritinib induces DNA damage and enhances PARP inhibitor responses in high-grade serous ovarian carcinoma.
    Cancer Res. 2021 Nov 22. pii: 0008-5472.CAN-21-0732.
    PubMed     Abstract available

  24. JAVELLANA M, Eckert MA, Heide J, Zawieracz K, et al
    Neoadjuvant chemotherapy induces genomic and transcriptomic changes in ovarian cancer.
    Cancer Res. 2021 Nov 4. pii: 0008-5472.CAN-21-1467.
    PubMed     Abstract available

    October 2021
  25. RAY U, Jung DB, Jin L, Xiao Y, et al
    Targeting LRRC15 inhibits metastatic dissemination of ovarian cancer.
    Cancer Res. 2021 Oct 15. pii: 0008-5472.CAN-21-0622.
    PubMed     Abstract available

    September 2021
  26. LECKER LS, Berlato C, Maniati E, Delaine-Smith R, et al
    TGFBI production by macrophages contributes to an immunosuppressive microenvironment in ovarian cancer.
    Cancer Res. 2021 Sep 24. pii: 0008-5472.CAN-21-0536.
    PubMed     Abstract available

  27. HENKLE TR, Lam B, Kung YJ, Lin J, et al
    Development of a Novel Mouse Model of Spontaneous High-Risk HPVE6/E7-Expressing Carcinoma in the Cervicovaginal Tract.
    Cancer Res. 2021;81:4560-4569.
    PubMed     Abstract available

    June 2021
  28. CHEN L, Zhai Y, Wang Y, Fearon ER, et al
    Altering the Microbiome Inhibits Tumorigenesis in a Mouse Model of Oviductal High-Grade Serous Carcinoma.
    Cancer Res. 2021;81:3309-3318.
    PubMed     Abstract available

    May 2021
  29. FARKKILA A, Rodriguez A, Oikkonen J, Gulhan DC, et al
    Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells.
    Cancer Res. 2021;81:2774-2787.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.